Akbar K Waljee1,2, Boang Liu3, Kay Sauder2, Ji Zhu3, Shail M Govani2, Ryan W Stidham2, Peter D R Higgins2. 1. VA Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, USA. 2. Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, MI, USA. 3. Department of Statistics, University of Michigan, Ann Arbor, MI, USA.
Abstract
Background and Aims: Vedolizumab (VDZ) is effective for Crohn's disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers. Methods: Phase 3 clinical trial data on VZD for CD were used to predict outcomes. Random forest modeling on the training cohort was used to predict the outcome of corticosteroid-free biologic remission at week 52 on the testing cohort. Models were constructed using baseline data, or data through week 6 of VDZ therapy. Results: The clinical trial included 594 subjects who received VDZ with baseline active inflammation [elevated C-reactive protein (>5 mg/L)]. Subjects with missing predictor variables (N = 120) or missing outcome data (N = 2) were excluded to produce a modeling dataset of 472 subjects. The Area Under the Receiver Operating Characteristic curve (AuROC) for corticosteroid-free biologic remission at week 52 using baseline data was only 0.65 (95% CI: 0.53 - 0.77), but was 0.75 (95% CI: 0.64 - 0.86) with data through week 6 of VDZ . Patients predicted to be in corticosteroid-free biologic remission at week 52 by the model achieved this endpoint 35.8% of the time, whereas patients predicted to fail only succeeded 6.7% of the time. Conclusions: An algorithm using laboratory data through week 6 of VDZ therapy was able to identify which CD patients with baseline inflammation would achieve corticosteroid-free biologic remission on VDZ at week 52. A majority of patients can be identified by week 6 as very unlikely to achieve remission.
Background and Aims: Vedolizumab (VDZ) is effective for Crohn's disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers. Methods: Phase 3 clinical trial data on VZD for CD were used to predict outcomes. Random forest modeling on the training cohort was used to predict the outcome of corticosteroid-free biologic remission at week 52 on the testing cohort. Models were constructed using baseline data, or data through week 6 of VDZ therapy. Results: The clinical trial included 594 subjects who received VDZ with baseline active inflammation [elevated C-reactive protein (>5 mg/L)]. Subjects with missing predictor variables (N = 120) or missing outcome data (N = 2) were excluded to produce a modeling dataset of 472 subjects. The Area Under the Receiver Operating Characteristic curve (AuROC) for corticosteroid-free biologic remission at week 52 using baseline data was only 0.65 (95% CI: 0.53 - 0.77), but was 0.75 (95% CI: 0.64 - 0.86) with data through week 6 of VDZ . Patients predicted to be in corticosteroid-free biologic remission at week 52 by the model achieved this endpoint 35.8% of the time, whereas patients predicted to fail only succeeded 6.7% of the time. Conclusions: An algorithm using laboratory data through week 6 of VDZ therapy was able to identify which CDpatients with baseline inflammation would achieve corticosteroid-free biologic remission on VDZ at week 52. A majority of patients can be identified by week 6 as very unlikely to achieve remission.
Authors: R W Stidham; T C H Lee; P D R Higgins; A R Deshpande; D A Sussman; A G Singal; B J Elmunzer; S D Saini; S Vijan; A K Waljee Journal: Aliment Pharmacol Ther Date: 2014-02-09 Impact factor: 8.171
Authors: Nicolas Williet; Gilles Boschetti; Marion Fovet; Thomas Di Bernado; Pierre Claudez; Emilie Del Tedesco; Camille Jarlot; Leslie Rinaldi; Anne Berger; Jean-Marc Phelip; Bernard Flourie; Stéphane Nancey; Stéphane Paul; Xavier Roblin Journal: Clin Gastroenterol Hepatol Date: 2016-11-24 Impact factor: 11.382
Authors: Sumin Bian; Erwin Dreesen; Ho Tsun Tang; Griet Compernolle; Miet Peeters; Gert Van Assche; Marc Ferrante; Séverine Vermeire; Ann Gils Journal: Inflamm Bowel Dis Date: 2017-12 Impact factor: 5.325
Authors: William J Sandborn; Brian G Feagan; Paul Rutgeerts; Stephen Hanauer; Jean-Frédéric Colombel; Bruce E Sands; Milan Lukas; Richard N Fedorak; Scott Lee; Brian Bressler; Irving Fox; Maria Rosario; Serap Sankoh; Jing Xu; Kristin Stephens; Catherine Milch; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: R W Stidham; T C H Lee; P D R Higgins; A R Deshpande; D A Sussman; A G Singal; B J Elmunzer; S D Saini; S Vijan; A K Waljee Journal: Aliment Pharmacol Ther Date: 2014-04-20 Impact factor: 8.171
Authors: M Rosario; N L Dirks; M R Gastonguay; A A Fasanmade; T Wyant; A Parikh; W J Sandborn; B G Feagan; W Reinisch; I Fox Journal: Aliment Pharmacol Ther Date: 2015-05-20 Impact factor: 8.171
Authors: Parambir S Dulai; Siddharth Singh; Xiaoqian Jiang; Farhad Peerani; Neeraj Narula; Khadija Chaudrey; Diana Whitehead; David Hudesman; Dana Lukin; Arun Swaminath; Eugenia Shmidt; Shuang Wang; Brigid S Boland; John T Chang; Sunanda Kane; Corey A Siegel; Edward V Loftus; William J Sandborn; Bruce E Sands; Jean-Frederic Colombel Journal: Am J Gastroenterol Date: 2016-06-14 Impact factor: 12.045
Authors: David Chen; Clifton Fulmer; Ilyssa O Gordon; Sana Syed; Ryan W Stidham; Niels Vande Casteele; Yi Qin; Katherine Falloon; Benjamin L Cohen; Robert Wyllie; Florian Rieder Journal: J Crohns Colitis Date: 2022-03-14 Impact factor: 10.020
Authors: Matthias Breidert; Pierre Eftekhari; François Louis; Claudia Rotoiu; Timo Rath; Markus F Neurath; Raja Atreya Journal: Crohns Colitis 360 Date: 2020-05-24
Authors: John Gubatan; Steven Levitte; Akshar Patel; Tatiana Balabanis; Mike T Wei; Sidhartha R Sinha Journal: World J Gastroenterol Date: 2021-05-07 Impact factor: 5.742
Authors: Akbar K Waljee; Beth I Wallace; Shirley Cohen-Mekelburg; Yumu Liu; Boang Liu; Kay Sauder; Ryan W Stidham; Ji Zhu; Peter D R Higgins Journal: JAMA Netw Open Date: 2019-05-03